Related Experiment Video

Updated: Jun 10, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K

Effectiveness of vigabatrin for infantile epileptic spasm syndrome categorized by etiologies

Hirokazu Takeuchi1, Kenjiro Kikuchi1, Rikako Takeda2

  • 1Division of Neurology, Saitama Children's Medical Center, Saitama, Japan; Department of Pediatrics, (The) Jikei University School of Medicine, Tokyo, Japan.

Seizure
|October 15, 2024
PubMed

Insights

Vigabatrin (VGB) effectiveness for infantile epileptic spasms syndrome (IESS) varies by cause. Tailoring VGB treatment to specific etiologies may improve outcomes for children with IESS.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Pharmacology

Background:

  • Infantile epileptic spasm syndrome (IESS) is a severe epilepsy syndrome.
  • Identifying effective treatments for IESS is crucial for improving patient outcomes.
  • Vigabatrin (VGB) is a commonly used antiepileptic drug for IESS.

Purpose of the Study:

  • To evaluate the effectiveness of vigabatrin (VGB) in treating infantile epileptic spasm syndrome (IESS).
  • To categorize IESS patients by etiology and analyze VGB effectiveness within these subgroups.

Main Methods:

  • Retrospective study of 41 IESS patients under 2 years old (excluding tuberous sclerosis).
  • VGB effectiveness assessed by sustained resolution of epileptic spasms (ES) and hypsarrhythmia absence for 3 months.
  • Etiologies categorized as genetic, congenital structural, acquired structural, and unknown.

Main Results:

  • Overall VGB effectiveness for IESS was 39.0%.
  • Effectiveness varied significantly by etiology: genetic (41.7%), congenital structural (9.1%), acquired structural (50%), and unknown (75%).
  • VGB showed higher effectiveness in trisomy 21 (28.6%) and perinatal brain injury (50%) subgroups.

Conclusions:

  • VGB effectiveness in IESS is significantly influenced by the underlying etiology.
  • Further research into VGB efficacy across IESS etiological subtypes is warranted.
  • Tailored treatment algorithms based on etiology could optimize VGB use in IESS management.
Abstract

Keywords:
EpilepsyEtiologyHypsarrhythmiaPerinatal brain injuryTrisomy 21West syndrome

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.5K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

20.2K

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
263
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
338
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
148
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
304
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
287